PURPOSE: To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphoma unspecified (PTCLU) with isolated skin involvement. PATIENTS AND METHODS: From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles. RESULTS: Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2). CONCLUSION: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
PURPOSE: To determine the antitumor activity of the proteasome inhibitor bortezomib in patients with cutaneous T-cell lymphoma (CTCL) or peripheral T-cell lymphomaunspecified (PTCLU) with isolated skin involvement. PATIENTS AND METHODS: From May 2005 to June 2006 at our institute, we treated patients with previously pretreated CTCL or PTCLU using bortezomib as a single agent, at a dose of 1.3 mg/m2 intravenously on days 1, 4, 8, and 11, every 21 days for a total of six cycles. RESULTS: Fifteen patients were registered, of whom 12 (10 CTCL, all mycosis fungoides, and two PTCLU with isolated skin involvement) were assessable. The overall response rate was 67%, with two (17%) complete remissions and six (50%) partial remissions. The remaining four patients had disease progression. Histologically, the responder patients were seven with CTCL and one with PTCLU with isolated skin involvement. All responses were durable, lasting from 7 to 14 or more months. Overall, the drug was well tolerated, with no grade 4 toxicity. The most common grade 3 toxicities were neutropenia (n = 2), thrombocytopenia (n = 2), and sensory neuropathy (n = 2). CONCLUSION: This study suggests that bortezomib was well tolerated and has significant single-agent activity in patients with cutaneous T-cell lymphoma.
Authors: Kieron Dunleavy; Richard L Piekarz; Jasmine Zain; John E Janik; Wyndham H Wilson; Owen A O'Connor; Susan E Bates Journal: Clin Cancer Res Date: 2010-12-01 Impact factor: 12.531
Authors: Rebecca L Boddicker; N Sertac Kip; Xiaoming Xing; Yu Zeng; Zhi-Zhang Yang; Jeong-Heon Lee; Luciana L Almada; Sherine F Elsawa; Ryan A Knudson; Mark E Law; Rhett P Ketterling; Julie M Cunningham; Yanhong Wu; Matthew J Maurer; Megan M O'Byrne; James R Cerhan; Susan L Slager; Brian K Link; Julie C Porcher; Deanna M Grote; Diane F Jelinek; Ahmet Dogan; Stephen M Ansell; Martin E Fernandez-Zapico; Andrew L Feldman Journal: Blood Date: 2015-04-01 Impact factor: 22.113
Authors: Ashish Juvekar; Subrata Manna; Sitharam Ramaswami; Tzu-Pei Chang; Hai-Yen Vu; Chandra C Ghosh; Mahmut Y Celiker; Ivana Vancurova Journal: Mol Cancer Res Date: 2011-01-11 Impact factor: 5.852
Authors: Beata Holkova; Victor Yazbeck; Maciej Kmieciak; Prithviraj Bose; Shuo Ma; Amy Kimball; Mary Beth Tombes; Ellen Shrader; Wen Wan; Caryn Weir-Wiggins; Amanda Singh; Kevin T Hogan; Sarah Conine; Heidi Sankala; John D Roberts; Thomas C Shea; Steven Grant Journal: Leuk Lymphoma Date: 2017-01-19